270
Participants
Start Date
September 30, 2011
Primary Completion Date
September 30, 2013
Study Completion Date
September 30, 2013
AVONEX PEN
Participants receive Avonex PEN commercially prescribed according to the local prescribing information.
Research Site, Glostrup Municipality
Research Site, Holstebro
Research Site, Næstved
Research Site, Amiens
Research Site, Clermont-Ferrand
Research Site, Créteil
Research Site, Nancy
Research Site, Rouen
Research Site, Strasbourg
Research Site, Aachen
Research Site, Bamberg
Research Site, Berlin
Research Site, Dresden
Research Site, Eisenach
Research Site, Erbach im Odenwald
Research Site, Freiburg im Breisgau
Research Site, Hamburg
Research Site, Heidenheim
Research Site, Herford
Research Site, Itzehoe
Research Site, Kastellaun
Research Site, München
Research Site, Nagold
Research Site, Potsdam
Research Site, Regensburg
Research Site, Rottweil
Research Site, Rüdersdorf
Research Site, Schwendi
Research Site, Siegen
Research Site, Sinsheim
Research Site, Stade
Research Site, Weil am Rhein
Research Site, Weisbaden
Research Site, Wolfratshausen
Research Site, 's-Hertogenbosch
Research Site, Eindhoven
Research Site, Heerlen
Research Site, Leeuwarden
Research Site, Sittard
Research Site, Bergen
Research Site, Drammem
Research Site, Førde
Research Site, Molde
Research Site, Tønsberg
Research Site, Amadora
Research Site, Košice
Research Site, Helsingborg
Research Site, Karlstad
Research Site, Linköping
Research Site, Norrköping
Research Site, Skövde
Research Site, Stockholm
Research Site, Trollhättan
Research Site, Lucerne
Research Site, Lugano
Research Site, Sankt Gallen
Research Site, Sion
Research Site, Dundee
Research Site, Glasgow
Research Site, Hammersmith
Research Site, Haywards Heath
Research Site, Irvine
Research Site, Leicester
Research Site, Sheffield
Lead Sponsor
Biogen
INDUSTRY